DeepNewz Markets

Markets Stories

Search

Loading...

Browse all stories on DeepNewz

Recursion and Exscientia to Merge in $688 Million All-Stock Deal

Aug 8, 2024, 12:02 PM

Recursion Pharmaceuticals and Exscientia have entered a definitive agreement to merge, creating a global leader in technology-enabled drug discovery. The merger, valued at $688 million, is an all-stock deal that will combine Recursion's high throughput target biology and supercomputing capabilities with Exscientia's generative AI drug design and chemistry automation. The collaboration is expected to enhance the companies' end-to-end capabilities in the biotech sector, marking a significant milestone in the use of AI in drug development.

View original story

Markets

Loading...

Looking for markets...

Will Recursion Pharmaceuticals' stock price increase by at least 20% by December 31, 2024, following the merger announcement?

Recursion Pharmaceuticals•Exscientia•Recursion

Resolution / Starting Odds

No • 50%

Yes • 50%

Stock market data from financial platforms such as Yahoo Finance, Bloomberg, or Reuters

Will the merger between Recursion Pharmaceuticals and Exscientia be completed by December 31, 2024?

Recursion Pharmaceuticals•Exscientia•Recursion

Resolution / Starting Odds

No • 50%

Yes • 50%

Official press releases from either Recursion Pharmaceuticals or Exscientia, financial news outlets such as Bloomberg or Reuters

Will the merger between Recursion Pharmaceuticals and Exscientia receive regulatory approval by December 31, 2024?

Recursion Pharmaceuticals•Exscientia•Recursion

Resolution / Starting Odds

Yes • 50%

No • 50%

Announcements from regulatory authorities such as the SEC or FTC, official press releases from either company

How many new drug discoveries will be announced by Recursion Pharmaceuticals and Exscientia post-merger by December 31, 2024?

Recursion Pharmaceuticals•Exscientia•Recursion

Resolution / Starting Odds

More than 3 new drugs • 25%

No new drugs • 25%

1 new drug • 25%

2-3 new drugs • 25%

Official press releases from Recursion Pharmaceuticals or Exscientia, announcements at biotech conferences, publications in scientific journals

How will the merger between Recursion Pharmaceuticals and Exscientia impact their market share in the biotech sector by December 31, 2024?

Recursion Pharmaceuticals•Exscientia•Recursion

Resolution / Starting Odds

Increase by 1-5% • 25%

Decrease • 25%

Increase by more than 5% • 25%

No significant change • 25%

Market analysis reports from financial institutions, industry reports from sources like Statista or MarketWatch

What will be the revenue growth for the combined entity of Recursion Pharmaceuticals and Exscientia by December 31, 2024?

Recursion Pharmaceuticals•Exscientia•Recursion

Resolution / Starting Odds

No increase or decrease • 25%

Increase by more than 20% • 25%

Increase by 10-20% • 25%

Increase by less than 10% • 25%

Financial reports from Recursion Pharmaceuticals and Exscientia, financial news outlets such as Bloomberg or Reuters